New FDA Approved Treatment for Sickle Cell Disease

Friday, September 20th, 2024 -- 8:00 AM

(Bob Hague, Wisconsin Radio Network) A newly FDA-approved treatment called Casgevy works by adding a gene that makes fetal hemoglobin, which reduces the clinical effects of sickle cell disease.

Before this new gene therapy was approved, the typical treatment could include daily oral medication and a bone marrow transplant in addition to transfusions to remove excess iron from the blood.

The Children’s Wisconsin program currently provides care for about 400 children living with sickle cell disease. Physicians estimate that the new treatment will include a two-month stay.

Feel free to contact us with questions and/or comments.